

# Ipercolesterolemia

## Punteggi AGREE delle Linee Guida selezionate

Le tabelle sottostanti riportano i punteggi AGREE Area Specifici delle diverse Linee Guida.

La percentuale in ciascuna casella rappresenta il punteggio standardizzato assegnato da 2 valutatori che indipendentemente hanno applicato lo strumento AGREE, ed esprimono in che misura la Linea Guida soddisfa il massimo punteggio ottenibile in ciascuna area.

### Legenda colori

	0-25%
	26-50%
	51-75%
	76-100%

		Area 1 Obiettivo e Motivazione	Area 2 Coinvolgimento delle parti in causa	Area 3 Rigore della elaborazione	Area 4 Chiarezza e presentazione	Area 5 Applicabilità	Area 6 Indipendenza editoriale
1	AHA	83%	42%	62%	71%	50%	92%
2	ATP 3	78%	42%	64%	67%	72%	42%
3	CCS	22%	17%	38%	17%	11%	67%
4	ESC	83%	38%	21%	38%	50%	75%
5	ICSI	94%	50%	33%	25%	44%	50%
6	JBS 2	94%	38%	7%	21%	33%	33%
7	MOH	89%	50%	36%	54%	22%	33%
8	NFI ITA	56%	42%	24%	38%	6%	17%
9	NHFA CSANZ	28%	38%	26%	63%	39%	75%
10	NICE	100%	83%	95%	100%	83%	100%
11	OSAKIDETZA	89%	29%	86%	100%	44%	83%
12	SIGN	94%	63%	86%	88%	83%	83%
13	USPSTF	100%	29%	52%	58%	0%	33%
14	VADOD	100%	54%	98%	100%	39%	42%
15	WHO	94%	50%	55%	83%	28%	42%

		Linee guida selezionate
1	<b>AHA 2007</b>	Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. 2005 <i>Circulation</i> 111:488-493
2	<b>ATP 3 2004</b>	(1) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) <a href="http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm">www.nhlbi.nih.gov/guidelines/cholesterol/index.htm</a> . (2) Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Circulation</i> 2004 110:227-239
3	<b>CCS 2006</b>	McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease <i>Can J Cardiol</i> 2006 22:913-927
4	<b>ESC 2007</b>	(1) Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) <i>Eur J Cardiovasc Prev Rehabil</i> 2007 14 Suppl 2:S1-113 (2) Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) <i>Eur J Cardiovasc Prev Rehabil</i> 2007 14 Suppl 2:E1-40
5	<b>ICSI 2007</b>	Institute For Clinical Systems Improvement (ICSI). Health Care Guideline: Lipid Management in Adults. 2007 <a href="http://www.icsi.org/guidelines_and_more/gl_os_prot/cardiovascular/lipid_management_3/lipid_management_in_adults__4.html">www.icsi.org/guidelines_and_more/gl_os_prot/cardiovascular/lipid_management_3/lipid_management_in_adults__4.html</a>
6	<b>JBS 2 2005</b>	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. <i>Heart</i> 2005 91(suppl. V): v1-v52
7	<b>MOH 2006</b>	MOH Clinical Practice Guidelines on Lipids 2006 <a href="http://www.moh.gov.sg/cpg">www.moh.gov.sg/cpg</a>
8	<b>NFI ITA 2008</b>	Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A et al Non-pharmacological control of plasma cholesterol levels <i>Nutr Metab Cardiovasc Dis</i> 2008 18(2): S1-16
9	<b>NHFA CSANZ 2005</b>	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Position Statement on Lipid Management. <i>Heart Lung and Circulation</i> 2005 14:275-291
10	<b>NICE 2008</b>	National Institute for Health and Clinical Excellence (NICE) Clinical guideline 67 Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2008 <a href="http://www.nice.org.uk/CG067">www.nice.org.uk/CG067</a>
11	<b>OSAKIDETZA 2008</b>	San Vicente Blanco R, Pérez Irazusta I, Ibarra Amarica J, Berraondo Zabalegui I, Uribe Oyarbide F, Urraca Garcia de Madinabeitia J, Samper Otxotorena R, Aizpurua Imaz I, Almagro Mugica F, Andrés Novales J, Ugarte Libano R. Guía de Práctica Clínica sobre el manejo de los lípidos como factor de riesgo cardiovascular <i>Osakidetza</i> 2008 Vitoria-Gasteiz <a href="http://www.guiasalud.es/viewGPC.asp?idGuia=433">www.guiasalud.es/viewGPC.asp?idGuia=433</a>
12	<b>SIGN 2007</b>	Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease Guideline n.97. 2007 <a href="http://www.sign.ac.uk/guidelines/fulltext/97/index.html">www.sign.ac.uk/guidelines/fulltext/97/index.html</a>
13	<b>USPSTF 2008</b>	US Preventive Services Task Force (USPSTF) Screening for Lipid Disorders in Adults. June 2008 <a href="http://www.ahrq.gov/CLINIC/uspstf/uspstf.htm">www.ahrq.gov/CLINIC/uspstf/uspstf.htm</a>
14	<b>VADOD 2006</b>	Department of Veterans Affairs/ Department of Defense (VA/DoD) Clinical practice guideline for the management of dyslipidemia. 2006 <a href="http://www.healthquality.va.gov/Dyslipidemia_LIPIDS.asp">www.healthquality.va.gov/Dyslipidemia_LIPIDS.asp</a>
15	<b>WHO 2007</b>	World Health Organization (WHO). Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk 2007 <a href="http://www.who.int/cardiovascular_diseases/guidelines/Prevention_of_Cardiovascular_Disease/en/index.html">www.who.int/cardiovascular_diseases/guidelines/Prevention_of_Cardiovascular_Disease/en/index.html</a>

## Ipercolesterolemia. Sintesi della qualità delle linee guida secondo i punteggi dello strumento AGREE

Le colonne riguardano i 6 domini relativi alla qualità delle 15 linee guida selezionate. Sull'asse verticale è riportata la percentuale cumulata di linee guida che ricade in uno dei 4 livelli di punteggio divisi in quartili (punteggio tra 0-25; punteggio tra 26-50; punteggio tra 51-75; punteggio tra 76-100). Il punteggio minimo è 0 (nessun parametro del dominio è soddisfatto dalla linea guida), quello massimo è 100 (tutti i parametri del dominio sono soddisfatti).

